Bristol-Myers Squibb confirms closure of Wallingford site

HARTFORD – A global biopharmaceutical company confirmed plans to close its location in Wallingford by the end of 2018. Bristol-Myers Squibb Company confirmed the previously announced plans to close the company’s Wallingford site and also announced it will no longer build a ‘Connecticut development’ site. The company said their domestic footprint will be focus on Central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts. The company will also be